Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12613846 | 0.85 | ALDH1A1 (0.40) | ALDH1A1HTTL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL12697265 | 0.85 | ALDH1A1 (0.40) | ALDH1A1HTTL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL16699597 | 0.83 | ALDH1A1 (0.46) | ALDH1A1HTTL3MBTL1MEN1KMT2A | |
| SCHEMBL7973185 | 0.83 | MEN1 (0.49) | ALDH1A1HTTL3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL7973187 | 0.83 | MEN1 (0.49) | ALDH1A1HTTL3MBTL1SMN1; SMN2MEN1 | |
| SCHEMBL26580348 | 0.83 | ALDH1A1 (0.46) | ALDH1A1HTTL3MBTL1GAAMEN1 | |
| SCHEMBL30707625 | 0.82 | ALDH1A1 (0.59) | ALDH1A1HTTL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL16700405 | 0.82 | GAA (0.47) | ALDH1A1HTTL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL12613037 | 0.78 | BCHE (0.42) | ALDH1A1HTTL3MBTL1GAAMEN1 | |
| SCHEMBL14720765 | 0.78 | KMT2A (0.38) | ALDH1A1HTTSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9061013-B2 | Isoxazoline derivatives as antiparasitic agents | ZOETIS LLC (US) | 2015-06-23 | — | — | US | disclosed |
| US-9061013-B2 | Isoxazoline derivatives as antiparasitic agents | ZOETIS LLC (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140011758-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC | 2014-01-09 | — | — | US | disclosed |
| US-20140011758-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC | 2014-01-09 | — | — | US | disclosed |
| WO-2012127347-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011758-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | CYP3A7, CYP2W1, CYP2A7 | ALDH1A1 276/4885HTT 2609/4885L3MBTL1 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.